Purified Psilocybin Compositions for Controlled Onset and Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals for treating mood disorders such as depression and anxiety have long onset times, severe side-effects, and poor efficacy, while psilocybin research is underdeveloped and poses risks due to variability and contamination in 'magic mushrooms, lacking proper formulations and studies.
Innovation Solution
Formulations of purified psilocybin derivatives and other serotonergic compounds in precise dosages, combined with terpenes and cannabinoids, to modulate neurotransmitter activity and mitigate negative effects, administered in controlled compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If purified psilocybin derivatives are formulated in precise dosages with terpenes and cannabinoids, then the onset time is reduced and efficacy is improved, but the formulation complexity and manufacturing precision requirements increase
Solution Approach 1:
The formulation is segmented into multiple functional components: purified psilocybin derivatives for primary therapeutic effect, terpenes for modulation and enhancement, cannabinoids for synergistic effects, and excipients for stability and delivery. This segmentation allows each component to be optimized independently while achieving rapid onset and reduced complexity in the overall formulation strategy.
Solution Approach 2:
The patent employs precise dosage parameters for each active ingredient, optimizing the concentration ratios of psilocybin derivatives, terpenes, and cannabinoids to achieve fast onset times. By carefully controlling these parameters within specific ranges, the formulation achieves rapid therapeutic effect without requiring overly complex manufacturing processes.
2Object-affected harmful factors
If purified psilocybin derivatives are used in precise dosages, then the side effects are reduced and safety is improved, but the manufacturing precision and quality control requirements increase
Solution Approach 1:
The patent extracts and isolates purified psilocybin derivatives from natural sources, removing contaminants and variability associated with raw 'magic mushrooms'. This extraction process concentrates the active ingredients in precise dosages, reducing side effects while establishing clear quality standards for manufacturing and quality control.
Solution Approach 2:
The formulation combines purified psilocybin derivatives with terpenes and cannabinoids in a composite material system. This composite approach distributes the therapeutic effect across multiple components, reducing the burden on any single ingredient and thereby reducing side effects, while the standardized ratios simplify manufacturing precision requirements.
3Ease of manufacture
If 'magic mushrooms' are used for psilocybin delivery, then the ease of manufacture and accessibility are improved, but the variability and contamination risks increase
Solution Approach 1:
Instead of using natural 'magic mushrooms' with variable compositions, the patent creates a standardized copy of the therapeutic effect using purified psilocybin derivatives in fixed dosages. This copied formulation replicates the desired therapeutic outcome while eliminating the variability and contamination risks of natural sources, maintaining accessibility through standardized manufacturing.
Data Source
AI summary
Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.